Haruka Handa

ARF6 and AMAP1 are major targets of <i>KRAS</i> and <i>TP53</i> mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer

Shigeru Hashimoto, Shotaro Furukawa, Ari Hashimoto et al. · Proceedings of the National Academy of Sciences · 2019 · 161 citations · Full text

Medicine, Cancer Biology, Oncology +16

Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer

Shigeru Hashimoto, Shuji Mikami, Hirokazu Sugino et al. · Nature Communications · 2016 · 117 citations · Full text

Medicine, Cancer Biology, Oncology +17

P53- and mevalonate pathway–driven malignancies require Arf6 for metastasis and drug resistance

Ari Hashimoto, Tsukasa Oikawa, Shigeru Hashimoto et al. · The Journal of Cell Biology · 2016 · 58 citations · Full text

Medicine, Cancer Biology, Oncology +17

Empagliflozin suppresses mitochondrial reactive oxygen species generation and mitigates the inducibility of atrial fibrillation in diabetic rats

Takuya Koizumi, Masaya Watanabe, Takashi Yokota et al. · Frontiers in Cardiovascular Medicine · 2023 · 58 citations · Full text

Life Sciences, Cardiology, Pharmacology +17

Succinyl-CoA-based energy metabolism dysfunction in chronic heart failure

Shingo Takada, Satoshi Maekawa, Takaaki Furihata et al. · Proceedings of the National Academy of Sciences · 2022 · 57 citations · Full text

Life Sciences, Biochemistry, Cardiology +17